Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 3 Inhibition of Sol-CXCL16 by Rosiglitazone In Vitro and In Vivo
(A) Down-regulation of sol-CXCL16 protein by rosiglitazone (Rosi) in mouse macrophages (*F = 38.4, p = 0.005; p < 0.01 rosiglitazone/LPS versus LPS alone). Cells were pretreated with rosiglitazone (1 µM x 24 h) and then with LPS (1 µg/ml x 24 h). (B) LPS-dependent induction of plasma sol-CXCL16 is blocked by rosiglitazone in mice (F = 8.83, p = 0.01). LDLR–/– mice (8 per group) were treated for 7 days with rosiglitazone (30 mg/kg) or vehicle and injected intraperitoneally with LPS (200 ng/g). Abbreviations as in Figure 1.
|
